TNF and inflammatory bowel disease: In contrast to infliximab and adalimumab, etanercept was associated with the development of paradoxical IBD, suggesting that other mechanisms beyond TNF-α neutralization are involved in the therapeutic effect of anti-TNF-α in IBD [109].